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Blood donations save millions of lives. However, 
unsafe transfusion practices put millions of people 
at risk for transfusion-transmissible infections 
(TTIs) (1). Indeed, with every unit of blood, there 
is a residual risk to become infected with a TTI 
agent, including mainly hepatitis B virus (HBV), 
hepatitis C virus (HCV), human immunodefi-
ciency virus (HIV), and syphilis (2). The first asso-
ciation of hepatitis with blood transfusion was in 
1943 (3). Today HBV infection is one of the most 
spread infections. Approximately 2 billion of 
world’s population has been infected and about 
400 million (5% of the world’s population) have 
chronic infection, more than 50 million people 
infected annually (4, 5). HCV infection is another 
common chronic infection, averaging 2-3% or 200 
million persons globally (6, 7). Despite the signifi-
cant reduction of the infection transmission risk 
Abstract 
Background: Transfusion-transmissible infections such as hepatitis B and hepatitis C are among the greatest threats 
to blood safety for transfusion recipients and pose a serious public health problem. The aim of this study was to assess 
the epidemiological aspects of hepatitis B and C in Kazakhstani donor’s blood over the period 2000-2011. 
Methods: The data were obtained from the annual reports of the Republican Blood Center. The retrospective study 
was conducted from 2000 to 2011. 
Results: Over the study period in the republic a growth of volumes of procured blood from 312.4 to 398.0 units was 
noted, in total equaled to 4,277.8 units. The proportion of blood wasted increased from 8.3% to 8.7%. In the dynam-
ics the proportion of viral hepatitis among all causes of blood wasted decreased from 29% to 15.5% (HBV) and from 
33.5% to 9.9% (HCV). The proportion of HBV and HCV in whole blood decreased considerably, in plasma and red 
cell concentrate the rates changed slightly. The average annual prevalence of HBV and HCV were 2.1% and 1.8%, 
respectively. 
Conclusion: Despite the reduction of viral hepatitis rates among blood donors in Kazakhstan the prevalence still re-
mains high. The HBV prevalence is higher compared to HCV, which needs further investigations in the general popu-
lation to address the issue. 
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over the past 20 years due to the selection of 
blood donors with low TTI marker risk followed 
by effective laboratory screening (8, 9), the risk of 
TTIs still remains a major concern (10). 
Kazakhstan is a post-Soviet newly independent 
country located in Central Asia, divided into 16 
geographical-administrative areas (14 regions and 
the cities of Astana and Almaty). Blood safety in 
the republic in respect of transmission of infec-
tious diseases is safeguarded by legislation that 
prescribes the selection of donors, both by pre-
donation questioning and serological testing. In 
accordance with international requirements, blood 
donors undergo mandatory screening tests for the 
presence of antibodies to HCV, HIV and syphilis, 
and HBV antigen. Donors who are reactive 
and/or positive are deferred and excluded (11). 
Another way of ensuring blood safety is identifica-
tion and retention of healthy blood donors (12), 
especially regular voluntary non-remunerated low-
risk donors (13). In most developing and transi-
tional countries family/replacement and paid 
blood donors are still a significant source of blood 
for transfusion (14). However, the possibility of 
contracting hepatitis is much higher among fam-
ily/replacement donors (15-17), and paid donors 
(18). 
The objective of this study was to assess the epi-
demiological aspects of Hepatitis B and C in do-
nor’s blood over the period 2000-2011. 
 
Materials and Methods 
 
The annual reports on the blood donations in the 
republic (form N39) compiled by the Republican 
Blood Center were extracted from the database of 
the Ministry of Health of the Republic of Kazakh-
stan. The data on the prevalence of HBV and 
HCV among donor’s blood were obtained. Data 
of the Agency of Statistics on the population of 
Kazakhstan and on the incidence of viral hepatitis 
were used (19). The time frame covers the period 
from 2000 to 2011. 
Our study describes the prevalence of hepatitis in 
whole blood, as well as in red cell concentrate and 
plasma, which are produced by method of plasma-
phoresis and cytaphoresis (20). After collecting a 
whole blood a small portion of it is left, the ma-
jority is processed in blood components. 
According to the law of the Republic of Kazakh-
stan «About State Statistics» (21), the information 
in the summary report is confidential and may on-
ly be used for statistical purposes. The infor-
mation may be shared for research purposes only 
if a requesting organization provides the data se-
curity and undertakes all the necessary actions in 
making unable the identity of respondents, in con-
cordance with the Principles of the World Medical 
Association (WMA) Declaration of Helsinki – 
Ethical Principles for Medical Research Involving 
Human Subjects, adopted by the 18th WMA Gen-
eral Assembly in Helsinki, Finland, in June 1964. 
In the study different methods of biomedical sta-
tistics were used – extensive and intensive indexes, 
average value, mean error, 95% confidence inter-
val and the average annual growth/decline rate (T, 
%) (22). The method of map compiling was used, 
based on the calculation of the standard deviation 
(σ) from the mean (x) (23). When grouping a par-
ametrical row for modeling equal intervals the 
formula proposed by Boyarsky (24) was used. 
Data collection and analysis was achieved by com-
piling the data on Microsoft Excel computing pro-





Between 2000 and 2011 in the republic a growth 
of volumes of procured blood from 312.4 to 
398.0 units was noted, in total equaled to 4,277.8 
units. The proportion of blood wasted also in-
creased from 8.3% to 8.7%.  
While the proportion of HBV and HCV among 
all blood discarded has decreased (Fig. 1). The 
average annual proportion of HBV was 25.0±2.0 
(95% CI=21.0-29.0), of HCV 21.3±2.6 (95% 
CI=16.2-26.5). 
According to the data of the Agency of Statistics 
the hepatitis are not differentiated according to 
types.  
Iranian J Publ Health, Vol. 43, No.2, Feb 2014, pp. 156-161 
158                                                                                                        Available at:    http://ijph.tums.ac.ir                         
 
 
Fig. 1: The proportion of hepatitis B and C in the total number of blood wastes for 2000-2011/ HBV+, positive test 
for hepatitis B antigen, HCV+, reactive/positive antibody test for hepatitis C 
 
Therefore, we considered the incidence of all 
types of viral hepatitis per 100,000 populations in 
whole over the country for 2000-2011. A signifi-
cant decrease from 185.6 to 16.2 was found. The 
regional features of the hepatitis distribution are 
shown in Table 1. The viral hepatitis incidences 




 Up to 40.8  From 40.8 to 141.4  Over 141.4 
 
Fig. 2: The map of all viral hepatitis incidence per 
100,000 population in Kazakhstan for 2000-2011. Re-
gions: 1. Akmola, 2. Aktobe, 3. Almaty, 4. Atyrau, 5. 
East-Kazakhstan, 6. Zhambyl, 7.West-Kazakhstan, 8. 
Karaganda, 9. Kostanay, 10.Kyzylorda, 11. Mangistau, 12. 
Pavlodar, 13. North-Kazakhstan, 14. South-Kazakhstan 
 
The total number of blood positive for TTI mark-
ers was 99,430 (5.2±0.4%) (95% CI=4.4-6.1). 
Among them the overall seroprevalence of HBV 
and HCV were 2.1±0.2% (95% CI=1.8-2.4) and 
1.8±0.2% (95% CI=1.2-2.2) respectively. 
The annual decline rates were −5.4% and −10.0%, 
respectively. Between 2000 and 2011 the HBV 
prevalence rate decreased from 2.5% to 1.3%, 
HCV prevalence rate also decreased from 2.8% to 
0.9%. The proportion of HBV and HCV in whole 
blood, plasma and red cell concentrate are illus-
trated in Fig. 3. Decline/growth rates of HBV 
were −31.6% (whole blood), +0.8% (plasma) and 
−0.8% (red cell concentrate), for HCV −31.5%, 
−4.4% and −5.7%, respectively. 
 
 
Fig. 3: The dynamics of hepatitis B (A) and hepatitis C 
(B) revealed in whole blood, plasma and red cell con-
centrate from 2000 to 2011 
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Table 1: The average annual incidence rate of viral hepatitis per 100,000 population in the Republic of Kazakh-
stan for 2000-2011 years 
 
Region/ city M±m 95% CI Т, % 
Pavlodar 19.1±6.5 6.5-31.8 −23.5 
West Kazakhstan 22.0±7.5 7.3-36.6 −22.7 
North Kazakhstan 29.9±8.5 13.2-46.7 −24.3 
Kostanay 32.5±7.2 18.4-46.7 −18.5 
Akmola 34.0±7.5 19.4-48.6 −16.1 
East Kazakhstan 37.1±6.8 23.7-50.4 −17.4 
Aktobe 47.4±12.7 22.4-72.3 −23.4 
Atyrau 49.5±21.4 7.6-91.3 −27.5 
Astana city 56.8±11.2 34.8-78.7 −17.5 
Karaganda 58.0±11.5 35.5-80.5 −16.2 
Almaty region 59.1±11.9 35.9-82.4 −14.5 
Almaty city 64.4±15.6 33.8-94.9 −20.3 
Mangistau 77.0±36.4 5.7-148.2 −31.3 
Zhambyl 104.2±21.5 62.1-146.3 −20.9 
South Kazakhstan 179.7±30.8 119.3-240.0 −21.5 
Kyzylorda 185.1±47.3 92.3-277.8 −21.5 




The objective of our study was to evaluate the 
prevalence of HBV and HCV in Kazakhstani 
blood donors. The average annual rate of HBV in 
this study was 2.1%, which is slightly lower when 
compared 2.58% found by Fessehaye et al. (25) in 
Eritrean donors, 4.7% in Pakistani donors and 15% 
in Egypt (26). However this index was higher than 
0.20% found by Cheraghali in Iranian donors (27) 
and 1.1% found by Ejele et al.(28) in Niger delta 
region of Nigeria. 
The average annual prevalence rate of HCV was 
equal to 1.8%, and this is high when compared to 
0.57% in Eritrea (25), 0.2% in Kenya (29) and 
0.06% in Iran (27). The prevalence was higher 
than values ranging between 0.072% and 0.6% 
reported from the USA and Albania (30, 31) but 
lower when compared to 2.7% in Egypt (32). 
In blood transfusion centers a small portion of the 
whole blood is left, and the rest is processed in the 
blood components (red cells concentrate, plasma 
etc.). According to the reporting form N39 the 
presence of HBV and HCV are defined both in 
whole blood and in its components. Over the 
study period the HBV seroprevalence in whole 
blood showed a considerable decreasing trend 
from 1.14% to 0.02%. In the red cell concentrate 
fraction the HBV slightly changed from 0.73% to 
0.67%, whereas in plasma an increase from 0.59% 
to 0.65% was noted. The aligned HCV prevalence 
rates had steadily decreased in whole blood, red 
cell concentrate and plasma from 1.25% to 0.02%, 
from 0.82% to 0.43% and from 0.69% to 0.42%, 
respectively (Fig. 3). The reduction in the presence 
of hepatitis virus markers in whole blood and 
slight changes in plasma and red cell concentrate, 
are probably due to the fact that in recent years 
whole blood transfusion is reducing, blood com-
ponent therapy is preferred and therefore most 
TTIs are revealed there. 
Regionally the lowest incidence rates of viral hepa-
titis in Kazakhstan were found in Pavlodar 
(19.1±6.5; 95% CI=6.5-31.8) and West Kazakh-
stan (22.0±7.5; 95% CI=7.3-36.6) regions. The 
highest rates were found in the South Kazakhstan 
(179.7±30.8; 95% CI=119.3-240.0) and Kyzylorda 
(185.1±47.3; 95% CI=92.3-277.8) regions. The 
incidence of viral hepatitis in the regions with low 
and high levels were significantly different 
(P<0.05). The objective causative-factor differ-
ences that effected the indicators, may possibly 
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relate to the accounting and registration questions, 
the preventive measures, the establishment of 
cause-effect relationship, and with other economic, 
medical-social, medical-geographical features in 
different regions of Kazakhstan. 
The epidemiological assessment of hepatitis rate 
over 12 years in donor’s blood showed a consid-
erable reduction. However, the prevalence of 
TTIs among blood donors in Kazakhstan still has 
an important focus of attention. The reduction of 
the TTI markers can be achieved by truly reliable 
information about the health condition of both 
repeat and first time donors, involvement of pref-
erably voluntary non-remunerated blood donors, 
comprehensive standardized screening of blood 
which are paramount for the organization of the 




The prevalence of hepatitis among donor’s blood 
in Kazakhstan still remains a major concern for 
the blood transfusion service. The HBV preva-
lence is higher compared to HCV and this needs 
further investigation including studying the preva-
lence rate of HBV in the general population to 
address the issue. The decreasing prevalence rate 
of HCV among Kazakh donors is an encouraging 
signal, which indicates the effectiveness of the 
changes introduced in the National Blood Trans-
fusion Service in line with the Ministry of Health 
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